QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=D6CE45891B758B23072D12349DA813EB;jsessionid=A78ED1FEEC9A13DD17CCC8E3368A4B4D;jsessionid=3182284DC925977BB7C20FAA48813BD4;jsessionid=E9C6CF2687D0337E3847E2F5AF5E8F81;jsessionid=3A0AF3FDACC0521757B77B117A5826BF;jsessionid=5132D2443EE806BDA3F65BB34B2CED4F;jsessionid=2C3FB68852B2FAC882D8F9F15334B941;jsessionid=C7E955DC82D5494EA93F9DB44DB89FC2 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
4. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.
5. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=D6CE45891B758B23072D12349DA813EB;jsessionid=A78ED1FEEC9A13DD17CCC8E3368A4B4D;jsessionid=3182284DC925977BB7C20FAA48813BD4;jsessionid=E9C6CF2687D0337E3847E2F5AF5E8F81;jsessionid=3A0AF3FDACC0521757B77B117A5826BF;jsessionid=5132D2443EE806BDA3F65BB34B2CED4F;jsessionid=2C3FB68852B2FAC882D8F9F15334B941;jsessionid=C7E955DC82D5494EA93F9DB44DB89FC2